Rx Prices Reflect “Anticipated Income,” Not R&D Costs, Pfizer CEO Says
Executive Summary
Pharmaceutical pricing decisions are based on "anticipated income" rather than achieving a return on R&D costs, Pfizer CEO Hank McKinnell writes in his recently published book A Call To Action: Taking Back Healthcare for Future Generations